NR4A1 and inflammatory bowel disease: CsnB, a pharmacological activator of Nur77 (44, 97), has been shown to exhibit anti-inflammatory effects in inflammatory bowel disease (89) and in cholesterol-induced THP-1 and U937 cells (91).